SCHEMBL30339075

SCHEMBL30339075

O=S(=O)(Nc1ccccn1)C1CC1

nearest known ligand 0.53

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ TSHR P16473 1/20 0.53
▸ ATM Q13315 1/20 0.53
▸ KDM4E B2RXH2 7/20 0.51
▸ LMNA P02545 3/20 0.51
▸ HSD17B10 Q99714 2/20 0.51
▸ MAPK1 P28482 2/20 0.51
▸ SMN1; SMN2 Q16637 2/20 0.49
▸ CKS1B P61024 2/20 0.48
▸ SKP2 Q13309 2/20 0.48
▸ TDP1 Q9NUW8 1/20 0.48
▸ ALDH1A1 P00352 3/20 0.46
▸ HPGD P15428 1/20 0.46
▸ POLB P06746 1/20 0.46
▸ PTGS1 P23219 1/20 0.46
▸ PTGS2 P35354 1/20 0.46
▸ SPR P35270 1/20 0.44
▸ MEN1 O00255 2/20 0.44
▸ KMT2A Q03164 2/20 0.44
▸ RXFP1 Q9HBX9 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14830949 1.00 TSHR (0.53) TSHRATMKDM4ELMNAHSD17B10
SCHEMBL30339221 0.77 PTGS1 (0.44) CKS1BSKP2TDP1PTGS1PTGS2
SCHEMBL31678766 0.77 PTGS1 (0.44) CKS1BSKP2TDP1PTGS1PTGS2
SCHEMBL27673212 0.77 TSHR (0.59) TSHRATMKDM4ELMNAHSD17B10
SCHEMBL25098943 0.77 TDP1 (0.49) TSHRKDM4ELMNAMAPK1CKS1B
SCHEMBL30339084 0.75 PTGS1 (0.46) CKS1BSKP2TDP1PTGS1PTGS2
SCHEMBL30338582 0.75 PTGS1 (0.46) CKS1BSKP2TDP1PTGS1PTGS2
SCHEMBL31678837 0.75 PTGS1 (0.43) CKS1BSKP2TDP1PTGS1PTGS2
SCHEMBL24369866 0.75 TDP1 (0.48) KDM4ESMN1; SMN2CKS1BSKP2TDP1
SCHEMBL5632154 0.73 TSHR (0.59) TSHRATMKDM4ELMNAHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230086703-A1 N-(4-(5-chloropyridin-3-yl)phenyl)-2-(2-(cyclopropanesulfonamido)pyrimidin-4-yl) butanamide derivatives and related compounds as human CTPS1 inhibitors for the treatment of proliferative diseases STEP PHARMA S.A.S. (FR) 2023-03-23 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230086703-A1 N-(4-(5-chloropyridin-3-yl)phenyl)-2-(2-(cyclopropanesulfonamido)pyrimidin-4-yl) butanamide derivatives and related compounds as human CTPS1 inhibitors for the treatment of proliferative diseases CTPS1, CTPS2, CERS2 TSHR 4097/4885ATM 4565/4885KDM4E 2434/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback